Posted by Michael Wonder on 26 Jan 2022
Immunocore announces FDA approval of Kimmtrak (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
26 January 2022 - Kimmtrak is the first T cell receptor therapeutic to receive regulatory approval.
Immunocore today announces approval from the United States FDA of Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01 positive adult patients with unresectable or metastatic uveal melanoma.
